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Abstract: Naïve, central- and effector-like memory regulatory T cells (Tregs) were evaluated in untreated and long-term 
antiretroviral-treated HIV+ patients that showed comparable CD4+ cell levels, while being, respectively, viremic and 
aviremic. In the untreated patients, the percentage of naïve-like Tregs was significantly increased to the detriment of 
central memory regulatory T cells. This redistribution of regulatory Treg subsets may contribute to explain the partially 
preserved CD4+ cell counts seen in these patients despite the ongoing viremia. On the contrary, in the long-term treated 
patients, the percentages of Treg subsets were similar to those of healthy donors, demonstrating a restored Treg 
homeostasis. The characterization of Treg subsets, rather than an evaluation of the total Treg population, may lead to a 
deeper understanding of the Treg role in HIV infection and therapy. 
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INTRODUCTION 
 The pathogenetic role of natural regulatory T cells 
(Tregs) in HIV infection is still ill defined. Treg-induced 
suppression can be deleterious for the development of an 
efficient anti-HIV specific immune response, but it may be 
also helpful in preventing an inappropriate immune 
activation [1,2]. Indeed, the increase of Tregs in HIV+ 
patients has been linked to a reduced immune activation and 
low viral load [2] but the accumulation of Tregs in lymphoid 
tissues was also found to be associated with a high viremia 
[3], both in infected patients and simian immunodeficiency 
virus-infected macaques [4]. The data about the frequencies 
of circulating Tregs in HIV+ patients are conflicting [5-7], 
most likely because of the different biological samples 
(whole blood vs separated peripheral blood cells) or patients 
being analyzed. For example, one study demonstrated a 
lower Treg frequency in viremic patients compared with 
aviremic subjects [8], while another showed an increased 
Treg frequency only in the viremic HIV+ individuals with a 
late-stage disease and with a reduced CD4+ cell number [9]. 
Another explanation of these discrepancies relies on the 
different procedures employed for the characterization of 
Tregs: initially, they have been identified with a suboptimal 
CD4+CD25high phenotyping [10,11]; then, using the more 
universally accepted CD4+CD25+FOXP3+ phenotype, which 
requires an intracellular staining [3,12]; more recently, Tregs 
have also been identified as CD4+CD25+CD127low/− cells 
because of a low expression of the IL-7 receptor (CD127) 
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and of a tight correlation with CD4+CD25+FOXP3+ cells 
[13-15]. 
 The heterogeneity of the Treg subpopulations [16], which 
include the naïve- (CD45RA+) and memory-like (CD45RA−) 
subpopulations [13,17], should be also taken into account. 
Among naïve Tregs, the expression of the CD31 antigen, 
which identifies T cells recently released from the thymus 
[18], allows the identification of “recent thymic emigrants” 
(RTE)-Tregs, which are important in the context of Treg 
homeostasis [19, 20]. Memory Tregs, similarly to 
conventional central memory (TCM) and effector memory 
(TEM) T cells, can be further divided into central memory-
like (TregCM) and effector memory-like (TregEM) on the basis 
of the chemokine receptor 7 (CCR7) expression [21, 22]. 
According to Menning et al. [23] the expression of the 
homing receptor CCR7 differentially regulates the in vivo 
function of Tregs: TregCM control the onset of immune 
responses in lymphoid organs like conventional CD4+ TCM 
cells, while TregEM modulate the suppressive phase in 
peripheral tissues [22]. Finally, according to the variable 
expression of FOXP3 and CD25 in CD45RA+ or CD45RA− 
cells, it is possible to identify two further subsets of Tregs 
endowed with different regulatory potential: resting Tregs 
(called rTregs [20] or naïve-like nTregs [24], depending on 
the study), which display the reduced suppressive capacity 
and properties of naïve cells, and activated Tregs (aTregs), 
which have an increased suppressive capacity and can be 
assimilated to memory-like Tregs [17, 20, 24]. 
 To our knowledge, no studies have analyzed all these 
subsets (naïve Tregs, RTE-Tregs, TregCM, TregEM, rTregs, 
and aTregs) in HIV-infected individuals. Therefore, we 
quantified all Treg subpopulations in two groups of HIV-
infected patients with similar CD4+ cell counts, one viremic 
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but not requiring treatment because of a relatively conserved 
number of CD4+ cells and the other aviremic because of a 
long lasting (more than 6 years) combined antiretroviral 
therapy (cART), in order to investigate whether the 
modulation of the different Treg subsets could help 
explaining the preserved immunity observed in the first 
group of patients. 
PATIENTS AND METHODS 
Patients 
 Two groups of patients were investigated. The first 
included 22 viremic HIV+ patients, who did not require 
therapy according to the current guidelines because of a 
sufficiently conserved CD4+ cell count, and because they did 
not manifest clinical signs of opportunistic infections or 
tumours. The second comprised 30 aviremic patients (plasma 
HIV-1 RNA <37 copies/mL for more than 6 years) under-
going long-term (>6 years) combination antiretroviral 
therapy (cART) with zidovudine, lamivudine, and lopinavir/ 
ritonavir, or tenofovir, lamivudine, and efavirenz, in whom 
the CD4+ cellular immunity was partially restored by stable 
therapy (Table 1). The study was conducted in accordance 
with good clinical practice (ICH-E6). The trial and 
amendments received approval by the institutional review 
board/independent ethics committee (resolution of n. 33 of 
March 11, 2011), and the patients provided written informed 
consent. Blood samples from 15 HIV− healthy donors (HD) 
were used as controls. 
Flow Cytometry Analysis 
 Treg subsets were determined by six-color flow 
cytometry on fresh whole blood obtained from untreated, 
cART-treated patients, and HD. Briefly, 100 µL of whole 
blood were stained with various combinations of optimal 
staining concentrations (previously determined by titrations) 
of allophycocyanin-H7 anti-CD4, fluorescein isothiocyanate 
anti-CD45RA (BD Pharmingen, Heidelberg, Germany), 
phycoerythrin anti-CD25, peridin-clorophyll protein-Cy5.5 
anti-CCR7 (BioLegend, San Diego, CA), phycoerythtin-Cy7 
anti-CD127 (eBioscience, San Diego, CA), and 
allophycocyanin anti-CD31 (Miltenyi Biotec, Bergisch 
Gladbach, Germany). The staining lasted for 15 minutes at 
room temperature and was followed by red blood cells lysis 
with BD Pharm Lyse™ lysing solution (BD Pharmingen). 
Data were collected using a BD FACSCanto II cytometer 
and analyzed with the FACSDiva software (BD Biosciences, 
San Jose, CA). Naïve, TCM, and TEM cells were respectively 
identified as CD4+CD45RA+CCR7+, CD4+ 
CD45RA−CCR7+, and CD4+CD45RA−CCR7− lymphocytes. 
Tregs, which were cells with a CD4+CD25+CD127low/− 
phenotype, were divided into: naïve Tregs, which were cells 
with a CD45RA+CCR7+ phenotype; TregCM, which were 
CD45RA−CCR7+ cells; and TregEM, which were CD45RA− 
CCR7− cells (Fig. 1A) [13-15]. RTE-Tregs were cells with a 
CD4+CD25+CD127low/−CD45RA+CCR7+CD31+ phenotype [19, 
20]. Finally, the subsets of nTregs and aTregs were recog-
nized as cells displaying, respectively, the CD4+ CD45RA+ 
CD25+ and CD4+CD45RA−CD25high phenotypes (Fig. 1B), 
whereas CD4+CD45RA-CD25+ were not considered in the 
analysis because they represent effector-like, cytokine 
secreting cells lacking suppressive capacity [20, 24]. 
Statistical Analysis 
 ANOVA or the Kruskal-Wallis test, according to the 
normality of the data distribution, followed by the Dunn’s 
post-hoc test were employed to compare the percentages and 
number of Tregs and Treg subpopulations (which are 
reported herein as medians and depicted as box-and-whisker 
plots). Analysis of covariance was also employed to adjust 
for the effect of the age. The Spearman’s test was used to 
assess correlations. Statistical significance was set at p<0.05. 
RESULTS AND DISCUSSION 
 The percentage and number of the total Tregs, identified 
as CD4+CD25+CD127low/− cells, did not differ in the 
untreated viremic and long-term treated aviremic patients 
from that of HD (7.8% vs 8.5% vs 8.6% and 47 cells/µL vs 
45 cells/µL vs 55 cells/µL; p=NS). A similar result was 
found when an analysis of covariance was performed to 
adjust for the effects of age (not shown). Differently from 
the above, by analysing the Treg subsets we found a 
redistribution of these cells in the untreated viremic patients, 
with an increase in the proportion (but not in the number) of 
naïve Tregs at the detriment of memory Tregs and, in 
particular, of the TregCM cells. Indeed, these cells were 
significantly decreased both in terms of percentage (Fig. 1C) 
and total number (not shown), while only the total number, 
and not the percentage, of TregEM was reduced (data not 
shown). 
 A differential redistribution of Treg subsets was also 
found when these cells were identified as nTregs and aTregs 
(Fig. 1D), which display features of naive-like and memory-
like Tregs, respectively [17, 20, 24]. We found, in fact, a 
Table 1. Immunological characteristics of included patients. Routine immunological and virological parameters of patients 
included in the study 
 
 UNT cART  p 
M:F 17:5 26:4 NS 
Mean age (range) 39 (23-54) 47 (36-58) <0.001 
CD4+ T cells (%) 30 (26-34) 32 (27-38) NS 
CD4+ T cells (cells/µL) 538 (455-691) 688 (407-822) NS 
CD4+/CD8+ T-cell ratio 0.7 (0.5-1) 0.8 (0.6-1.1) NS 
HIV-1 RNA (copies/mL) 14 155 (263-33 380) <37 (37-37) <0.01 
UNT: HIV-infected patients not needing treatment; cART: HIV-infected treated with cART for more than 6 years. p: p-value obtained by the Mann-Whitney test. 
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significant increase of nTregs only in the untreated viremic 
patients and a strong positive correlation between the 
percentage of naive Tregs and nTregs, both when data were 
analyzed altogether (r=0.83, p<0.001) and in each patient 
group (Fig. 1E). Likewise, positive correlations were present 
between the total percentage of memory Tregs (TregEM + 
TregCM) and aTregs (Appendix Fig. 1). These changes in the 
Treg subset redistribution were not due to the known effects 
of age on new T-cell production because the analysis of 
covariance did not detect any significant group-specific age-
mediated effect (p=0.31), but confirmed that the population 
of naïve Treg cells was more represented in the untreated 
than in cART-treated patients and HD (age-adjusted means: 
45.8% vs 36.6% vs 32.2%, respectively; p<0.001). 
 The increased naive Tregs were not likely to result from 
an increased output of naive Tregs from the thymus because 
 
Fig. (1). Quantification of the Treg subpopulations. A. CD4+ cells, gated on lymphocytes, were first analyzed for the expression of the 
CD25 and CD127 surface antigens (Tregs defined as CD4+CD25+CD127low/−). The subsequent phenotyping based on the expression of 
CD45RA and CCR7 on the Treg population, as shown in the representative plot, allowed the distinction of Tregs into naïve 
CD4+CD25+CD127low/−CD45RA+CCR7+, central-memory-like (TregCM) CD4+CD25+CD127low/−CD45RA−CCR7+ and effector memory-like 
(TregEM) CD4+CD25+CD127low/−CD45RA−CCR7− populations. B. On CD4+ cells, naive-like nTregs were gated as CD45RA+CD25+ cells, 
and memory-like aTregs as CD45RA−CD25high cells. C. Percentage of Tregs with a naïve, TregCM, and TregEM phenotype in untreated 
(UNT), long-term combination antiretroviral therapy (cART)-treated patients, and healthy donors (HD). Horizontal lines indicate the 
significant differences between groups. The percentages of naïve Tregs, TregCM, and TregEM were also significantly different when compared 
within each group, exception made for the naïve Tregs and TregCM, which were not different within HD (significance lines not displayed). D. 
Quantification of nTregs and aTregs as a proportion of CD4+ cells in patients (UNT, cART) and HD. Horizontal lines indicate the significant 
differences between groups. E. Correlations between the measures of naive Tregs and nTregs in patients (UNT, cART) and HD. Lines 
obtained by linear regression analysis. F. Correlations between the Treg subsets and CD4+ cell counts in the cART-treated patients. Lines 
obtained by linear regression analysis. ***: p<0.001; **: p<0.01; *: p<0.05. 
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RTE-Tregs, which represent the subset of Tregs recently 
released from the thymus [19, 20], were not different in the 
three groups (4% vs 4% vs 4%, and 4.7 cells/µL vs 8.5 
cells/µL vs 6 cells/µL; p=NS), even if data were age-adjusted 
(not shown). Thus, the present findings may be explained by 
a slow differentiation rate of naïve Tregs into TregCM and/or 
a preferential infection and killing of TregCM [25]. Memory 
Tregs are in fact highly proliferative compared to their naïve 
counterparts, and in this situation, which favours viral 
replication [26], TregCM could represent a population more 
prone to apoptosis [20]. Accordingly, we found that a higher 
viral load correlated with a lower percentage of TregCM 
(r=−0.51; p=0.016). Thus, an accelerated turnover of TregCM 
in conditions of high viral replication could drive a 
homeostatic expansion of naïve Tregs, whose proportion, in 
turn, was found to be positively correlated with the viremia 
(r=0.51; p=0.017). This interpretation implies the assumption 
that homeostatically expanded naive cells accumulated 
because unable to differentiate into memory cells, in contrast 
to what would be normally expected [27]. Indeed, whereas 
this process is normally dependent on IL-7 stimulation [27], 
in naive Tregs of viremic patients the downstream parts of 
IL-7 signalling machinery are known to be disrupted [28]. 
 Alternatively, the reduced proportion of circulating 
TregCM in the blood of untreated patients could merely 
reflect an enhanced retention of this population in lymphoid 
organs. In fact, while TregCM and TregEM should not differ in 
terms of regulatory capacity [22], the differential expression 
of CCR7 empowers them to migrate to the lymphoid and the 
peripheral tissues, respectively, to perform their suppressive 
functions [22, 23]. In the lymphatic tissues, TregCM might 
underlie an increased immune suppression that would be 
responsible, on one hand, of a less efficient control of viral 
replication (shown by the residual viremia), and, on the other 
hand, of a lower degree of chronic immune activation, 
which, in turn, could explain the conserved CD4+ cell 
number present in the viremic patients even if untreated. 
Interestingly, this interpretation fits with observations made 
in African green monkeys infected by simian 
immunodeficiency virus [4]. 
 Differently from the untreated, in the cART-treated 
patients the percentage of naïve and TregCM were similar to 
that of HD (in whom TregCM is usually the most represented 
subset) [29]. In addition, only in treated patients and not in 
the untreated (data not shown), a highly significant, strong 
positive correlation between the percentage of naïve Tregs 
and the CD4+ cell count, and an inverse correlation between 
TregCM and CD4+ cells were found (Fig. 1F). As already 
suggested by Simonetta et al. [17], this indicated that the 
relationship between naïve Tregs and the CD4+ cell count is 
restored by the long lasting cART. On the other hand, our 
data differ from those of the same authors reporting that the 
naïve-like Treg number was preserved in HIV-infected 
patients regardless of treatment [17]. This discrepancy could 
be explained either by the different methodological 
approaches, or by the different HIV plasma levels in the 
patients of the two studies. The strong correlation found 
between the percentage of naive Tregs and the viral load 
(r=0.51, p=0.016) supports the second hypothesis. Therefore, 
although performed with different methodological 
approaches and type of patients, our study, at least in part, 
complements that of Simonetta et al. [17] by demonstrating 
that a long lasting effective cART restores Treg homeostasis, 
most likely by hampering HIV replication in the periphery 
and into the lymphoid sanctuaries [30, 31]. 
 It is also not straightforward to compare our results with 
those by Zhou et al. [24], who found that nTregs were 
greatly reduced while aTregs were increased in chronically 
infected, treatment-naive viremic patients (but not in those 
acutely-infected). Indeed, in the mentioned study patients 
were therapy-naive at the time of recruitment, and then 
started treatment because of disease progression, whereas 
our untreated patients were stable, chronically infected 
subjects never undergoing treatment throughout the study 
period. On the other hand, even if we could not perform a 
Treg quantification before treatment beginning, our findings 
in the long-term cART-treated patients are in agreement with 
those of Zhou et al. [24] in demonstrating that the extent of 
post-therapy nTreg recovery relied on the amount of CD4+ 
cell number before therapy. Indeed, by stratifying our 
patients in two groups on the basis of the routinely-tested 
pre-therapy CD4+ cell number, we found that the higher 
median percentage of both naive Tregs (33% vs 23%, 
p=0.046) and nTregs (2.10% vs 1.23%, p= 0.010) was 
measured in the group of patients with a baseline CD4+ cell 
count over 200 cells/µL. 
 In the context of our study, one concern may arise from 
the method employed to identify Treg cells, because the 
down-regulation of CD127 due to the HIV-induced chronic 
immune activation [32, 33] may lead to an overestimation of 
Tregs in viremic patients, when these cells are identified 
only according to the lack of CD127 and not to the presence 
of FOXP3 [8]. However, also the more commonly used Treg 
marker FOXP3 is transiently up-modulated after cell 
activation in a fraction of effector, non-regulatory cells [34], 
and FOXP3+CD25+CD45RA− cells have also been reported 
to be non-regulatory [20]. Furthermore, even in viremic 
patients, the overwhelming majority of CD25highCD127low 
cells have been shown to coincide with the FOXP3high 
population [7]. To definitively rule out the possibility that 
our results could be technically biased, we analyzed the 
expression of the CD127 marker within the total naive and 
memory T-cell subsets. In contrast to the selective increase 
of CD127low/− cells within the naive Treg subset and to their 
decrease within the TregCM or TregEM subsets in the 
untreated viremic patients (Fig. 1C), an increased frequency 
of CD127low/− cells was found within the TCM and TEM 
subsets, but not within the naive one in the same patients 
(Fig. 2). This result indicates that the present findings are not 
an artefact mirroring the chronic immune cell activation 
typical of viremic patients, but are likely to represent a 
modulation of bona fide Treg cell subsets. 
 In conclusion, we propose that the redistribution of Treg 
subsets contributes to explain the partially preserved CD4+ 
cell counts despite the ongoing viremia seen in untreated 
patients. Therefore, an analysis of the fine modulation of the 
Treg subsets, rather than a study of the total Treg population, 
should be performed for a better understanding of the Treg 
role in HIV infection and therapy. However, the 
heterogeneity of HIV patients and methods advocates the 
need of further studies, aimed at identifying the most 
appropriate Treg definition in the different subsets of HIV 
patients. 
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Fig. (2). Expression of CD127 in non-regulatory T cell subsets. Percentages of CD127low/− cells among naïve, TCM, and TEM CD4+ cells in 
untreated (UNT), long-term combination antiretroviral therapy (cART)-treated patients, and healthy donors (HD). 
APPENDIX 
 
Appendix Fig. (1). Correlation between the percentage of memory Tregs (TregCM + TregEM) and aTregs in all patients and controls (A), in 
untreated patients (B), and in long-term treated patients (C). Lines are obtained by linear regression. UNT: untreated patients; cART: patients 
treated for more than 6 years with a combined antiretroviral therapy. 
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